SARS-CoV-2: Viral Mechanisms and Possible Therapeutic Targets — What to Learn from Rheumatologists

To the Editor:

It was with great interest that we read the editorial by Drs. Cron and Chatham linking the cytokine storm syndrome (CSS) seen in macrophage activation syndrome, common in the rheumatological setting, with a CSS postulated to be a background in the novel coronavirus (SARS-CoV-2) infection. Amid the high contagion of the virus, science was also infected by an infodemic, compelled to finish the race to find effective therapies, while physicians managed real-world patients.

Molecular evidence has shown that SARS-CoV-2, by using the angiotensin-converting enzyme 2, enters in alveolar epithelial and endothelial cells, as well as macrophages. The TMPRSS2 protease induces virus–cell membrane fusion at the cell surface and facilitates entry of coronaviruses into the host cell. Once the coronavirus disease 2019 (COVID-19) enters the cell, it uses the RNA polymerases and protease inhibitors to synthesize and secrete a mature virion. After that, the virion interacts with Toll-like receptors (TLR), causing an imbalance in the pro- and anti-inflammatory cytokines. In addition to TLR, the enzyme AP-2–associated protein kinase I works in viral cellular entry with Janus kinase and signal transducer and activator of transcription (JAK-STAT) pathways, contributing to this process.

Those molecular interactions may result in the secretion of countless cytokines such as interleukin (IL)-6, IL-1β, and interferon-β, depending on the patient’s immune status. According to some studies, the severity of the disease can be signaled by identifying this storm of cytokines, suggested by laboratory characteristics such as lower white cell and platelet count, and high C-reactive protein, lactate dehydrogenase, and ferritin levels, all similar to hemophagocytic lymphohistiocytosis (HLH). In this stormy stage, drugs that reduce viremia may not be as effective, and minimizing the damage caused by the inflammatory process should be prioritized. We saw in previous pandemics that immunosuppressed patients (e.g., rheumatic and post-transplant patients) did not evolve to the unfavorable outcome as frequently as expected, strengthening the rationale that immunosuppression may be the key. Yet it should be kept in mind that the inflection point between viremia and inflammatory response is a continuum. This signals that we may be able to, through molecular analyses of the virus-cell relationship, identify specific therapeutic targets at different stages of the disease.

Therefore, understanding the virus-cell interaction and the binomial viral load and immune response can help us to make better choices from among the different therapeutic strategies for different phases of the disease.

Table 1. Biological plausibility and therapeutic options.

<table>
<thead>
<tr>
<th>Viral Mechanism</th>
<th>Drug Rationale</th>
<th>Suggested Therapy</th>
<th>Current Research Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>The SARS-CoV-2 after entering the cell, uses the cellular machinery to synthesize and secrete a mature virion.</td>
<td>Inhibition of RNAP and protease</td>
<td>Inhibitors of RNAP (e.g., remdesivir and favipiravir) and protease inhibitors (e.g., lopinavir and ritonavir)</td>
<td>Primary studies with lopinavir/ritonavir did not show clinical improvement or reduction in mortality. The use of remdesivir in rheumatoid arthritis and in patients infected with SARS-CoV-2 was effective in reducing clinical disease and lung damage.</td>
</tr>
<tr>
<td>The TMPRSS2 protease cleaves coronavirus glycoproteins (called spike proteins), which induces virus–cell membrane fusion at the cell surface and facilitates entry of coronaviruses into the host cell.</td>
<td>Inhibition of TMPRSS2</td>
<td>Camostat mesylate</td>
<td>There are no clinical trials specifically testing these drugs as yet, although there are studies suggesting its off-label use.</td>
</tr>
<tr>
<td>The mature virion interacts with TLR to stimulate inflammatory pathways and regulate the production of proinflammatory cytokines. JAK 1 and 2 are implicated in inflammation pathways, and the enzyme AAK1 works in viral cellular entry. showed</td>
<td>Inhibition of endosomal TLR activation</td>
<td>Chloroquine and HCQ</td>
<td>Some studies showed no effectiveness while others showed reduction in the recovery time for cough and fever.</td>
</tr>
<tr>
<td>IL-6 production through TLR. IL-6 induces lung inflammation, fever, and fibrosis.</td>
<td>IL-6 inhibition</td>
<td>TCZ, sarilumab</td>
<td>A small, open-label, non-randomized pilot study with patients presenting moderate COVID-19 pneumonia that in the baricitinib-treated group, all clinical characteristics and respiratory function variables significantly improved when compared to baseline. A small retrospective study observed that symptoms, hypoxemia, and CT opacity changes were improved shortly after the treatment with tocilizumab (IL-6 blocker), suggesting that inhibition of IL-6 pathway could be an efficient target for the treatment of COVID-19.</td>
</tr>
</tbody>
</table>

Thus, the study of inflammatory pathways seems to be an assertive choice in the pursuit of an efficient and safe target for SARS-CoV-2. It prevents the disposal of a possibly effective treatment simply because it has been tested at an unsuitable stage. Indeed, biological plausibility, despite its limited applicability in real life due to in vivo variables not considered in vitro, is still a good starting point for scientific development. When chaos exists and there is an urgent need for quick answers, the best evidence, with all its flaws, is usually intuition and prior knowledge. Balancing them with the security required by the primum non nocere principle is the essence of medical bedside care. This pandemic can rescue science from the fallacy that its function is to predict the future and be the owner of the truth. In fact, science is moved by uncertainty. As the physicist Cesar Lattes wisely said, “Science cannot predict what will occur. It can only calculate the probability of something happening.” So, time will tell whether today’s science is right or wrong.

Carlos Antonio Moura1,2, MD, Professor
Carlos Geraldo Moura1,3, MD, PhD, Director of Internal Medicine Residency Program, Professor
Ana Luísa Cerqueira De Sant’ana Costa4, MD, Resident in Internal Medicine
1Santo Antonio Hospital’s Internal Medicine Residency Program (Irmã Dulce’s Social Works);
2Salvador University (UNIFACS);
3Bahiana School of Medicine and Public Health;
4Santo Antonio Hospital (Irmã Dulce’s Social Works), Salvador, Bahia, Brazil.

Address correspondence to Dr. A.L. Cerqueira De Sant’ana Costa,
Avenida Bonfim, 161 Largo de Roma, Salvador, Bahia 40.420-415, Brazil.
Email: caggmoura@yahoo.com.br.

REFERENCES